Verily, Google’s life sciences and healthcare arm, has announced a major restructuring that includes layoffs and the shutdown of its medical devices program. CEO Stephen Gillet told staff in a memo that the company must make “difficult decisions” to focus resources on its core priorities of precision health, data, and AI. The exact number of employees affected was not disclosed, but the move marks a big shift for Verily, which has spent years building devices like the Dexcom G7 glucose monitor, retinal imaging tools, and clinical study wearables.
Gillet praised the Devices team for their decade-long contributions to advancing healthcare technology, saying their work has left a lasting impact on patients and research. While the program is ending, Verily will continue to support existing tools in active clinical trials, such as the Numetric Watch.
For employees staying with the company, Gillet stressed that the mission remains exciting and important, but acknowledged the transition will be tough as colleagues and friends depart. He urged patience and commitment as Verily narrows its focus. The company says these cuts are part of “deliberate choices about resourcing” meant to accelerate its path to commercial success.
https://timesofindia.indiatimes.com/technology/tech-news/googles-moonshot-division-verily-to-cut-jobs-what-ceo-stephen-gillett-told-laid-off-employees-in-memo/articleshow/123580591.cms